Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and b...

ανά Hilborn, Erik, Stål, Olle, Jansson, Agneta
Τόπος έκδοσης Oncotarget (2017)

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breas...

ανά Hilborn, Erik, Stål, Olle, Alexeyenko, Andrey, Jansson, Agneta
Τόπος έκδοσης Oncotarget (2017)

Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer

ανά Busch, Susann, Rydén, Lisa, Stål, Olle, Jirström, Karin, Landberg, Göran
Έκδοση 2012

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

ανά Wegman, Pia, Elingarami, Sauli, Carstensen, John, Stål, Olle, Nordenskjöld, Bo, Wingren, Sten
Έκδοση 2007

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients

ανά Hilborn, Erik, Sivik, Tove, Fornander, Tommy, Stål, Olle, Nordenskjöld, Bo, Jansson, Agneta
Έκδοση 2014

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

ανά Hilborn, Erik, Gacic, Jelena, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle, Jansson, Agneta
Τόπος έκδοσης Br J Cancer (2016)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

ανά Nordenskjöld, Anna, Fohlin, Helena, Fornander, Tommy, Löfdahl, Britta, Skoog, Lambert, Stål, Olle
Τόπος έκδοσης Breast Cancer Res Treat (2016)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

ανά Karlsson, Elin, Veenstra, Cynthia, Gårsjö, Jon, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle
Τόπος έκδοσης J Cancer Res Clin Oncol (2018)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

ανά Jerevall, Piiha-Lotta, Jansson, Agneta, Fornander, Tommy, Skoog, Lambert, Nordenskjöld, Bo, Stål, Olle
Έκδοση 2010

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer

ανά Sivik, Tove, Gunnarsson, Cecilia, Fornander, Tommy, Nordenskjöld, Bo, Skoog, Lambert, Stål, Olle, Jansson, Agneta
Έκδοση 2012

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

ανά Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle
Τόπος έκδοσης Oncol Lett (2020)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

ανά Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle
Τόπος έκδοσης Mol Clin Oncol (2020)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

ανά Wegman, Pia, Vainikka, Linda, Stål, Olle, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars-Erik, Wingren, Sten
Έκδοση 2005

Exploring cancer register data to find risk factors for recurrence of breast cancer – application of Canonical Correlation Analysis

ανά Razavi, Amir R, Gill, Hans, Stål, Olle, Sundquist, Marie, Thorstenson, Sten, Åhlfeldt, Hans, Shahsavar, Nosrat
Έκδοση 2005

Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer

ανά Lundgren, Katja, Tobin, Nicholas P., Lehn, Sophie, Stål, Olle, Rydén, Lisa, Jirström, Karin, Landberg, Göran
Έκδοση 2011

Akt kinases in breast cancer and the results of adjuvant therapy

ανά Stål, Olle, Pérez-Tenorio, Gizeh, Åkerberg, Linda, Olsson, Birgit, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars Erik
Έκδοση 2003

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

ανά Lehn, Sophie, Tobin, Nicholas P, Sims, Andrew H, Stål, Olle, Jirström, Karin, Axelson, Håkan, Landberg, Göran
Έκδοση 2014

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer

ανά Schroeder, Brock, Zhang, Yi, Stål, Olle, Fornander, Tommy, Brufsky, Adam, Sgroi, Dennis C., Schnabel, Catherine A.
Τόπος έκδοσης NPJ Breast Cancer (2017)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer

ανά Bostner, Josefine, Alayev, Anya, Berman, Adi Y., Fornander, Tommy, Nordenskjöld, Bo, Holz, Marina K., Stål, Olle
Τόπος έκδοσης Breast Cancer Res Treat (2017)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype

ανά Veenstra, Cynthia, Karlsson, Elin, Mirwani, Sanam Mirwani, Nordenskjöld, Bo, Fornander, Tommy, Pérez-Tenorio, Gizeh, Stål, Olle
Τόπος έκδοσης J Cancer Res Clin Oncol (2019)